DRUG SHARE OF MEDICAL COSTS DROP
Last month the Japanese Ministry of Health published figures from its medical care survey showing that in 1990 the percentage of drug costs in total medical expenditures bill dropped 2.7 points to 28.6%, according to Pharma Japan, which said that this reflects the reduction in reimbursement prices.
This rise, it added, is nearly equal to the virtual increase, after exclusion of the effects of the reimbursement price cuts, in medical fees that took place in 1990. The Ministry's survey was based on 260,000 applications for reimbursement under government-managed employee health insurance programs inspected in June 1990, covering dental and medical fields.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze